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Breast cancer is the most common cancer detected in women and current screening methods for 
the disease are not sensitive. Volatile organic compounds (VoCs) include endogenous metabolites 
that provide information about health and disease which might be useful to develop a better 
screening method for breast cancer. The goal of this study was to classify mice with and without 
tumors and compare tumors localized to the mammary pad and tumor cells injected into the iliac 
artery by differences in VOCs in urine. After 4T1.2 tumor cells were injected into BALB/c mice either 
in the mammary pad or into the iliac artery, urine was collected, VOCs from urine headspace were 
concentrated by solid phase microextraction and results were analyzed by gas chromatography-mass 
spectrometry quadrupole time-of-flight. Multivariate and univariate statistical analyses were employed 
to find potential biomarkers for breast cancer and metastatic breast cancer in mice models. A set of six 
VOCs classified mice with and without tumors with an area under the receiver operator characteristic 
(ROC AUC) of 0.98 (95% confidence interval [0.85, 1.00]) via five-fold cross validation. Classification of 
mice with tumors in the mammary pad and iliac artery was executed utilizing a different set of six VOCs, 
with a ROC AUC of 0.96 (95% confidence interval [0.75, 1.00]).
Breast cancer is the most commonly diagnosed cancer among all women worldwide, but there is no accurate 
and non-invasive method to screen for breast cancer in patients before a confirmatory biopsy is performed1. 
Implementing an accurate and non-invasive screening technique is important because the earlier that a cancer-
ous tumor is found in the human body, the more efficient treatment will be2. The current non-invasive screening 
methods that are used to screen for breast cancer include mammography and ultrasounds, but these screening 
techniques are not sensitive or specific, which leads to many false positive results. Overall, these methods lead to 
over-diagnosis and over-treatment3. Another non-invasive screening method that can be used to screen for breast 
cancer is detecting hypermethylation of DNA in nipple aspirate fluid4, but sample collection poses a challenge. 
Urine contains volatile organic compounds (VOCs) that are products of metabolic pathways and may serve as a 
source of biomarkers for breast cancer5,6. VOC biomarker discovery is promising because there are thousands of 
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VOCs that are present in urine, breath and blood samples that have the potential to be biomarkers for an array of 
diseases7,8. The detection of VOCs has been a recent alternative screening technique for many different diseases 
that has been shown to be sensitive and specific. Analyzing urine samples for metabolic biomarkers is also rela-
tively inexpensive compared to other traditional techniques3. Implementing a non-invasive and accurate breast 
cancer diagnostic technique based on sensing metabolic VOCs associated with the disease can lead to an increase 
in early diagnosis9.
An alternative sample that could be collected to analyze VOCs as potential biomarkers for breast cancer is 
biological breath10–13. Phillips et al. discovered a set of VOCs found in human breath that distinguished between 
patients with and without breast cancer with 78.5% sensitivity and 84.8% specificity in their training data set10. 
Even though some cancer VOC biomarkers have been identified in human breath, analyzing urine can provide 
better insight into metabolic biomarkers. For example, urine has relatively higher concentrations of metabolic 
VOCs than breath, which makes them easier to detect14. Analysis of cell line VOCs is another technique utilized 
to discover biomarkers related to breast cancer3,15. Silva et al. (who previously analyzed human urine VOCs)14 
reported a set of VOCs that distinguish between breast cancer and healthy cultured cells. One-way ANOVA 
initially identified VOCs statistically significantly different between healthy and breast cancer cell lines, and then 
Principal Component Analysis (PCA) and Linear Discriminant Analysis (LDA) were utilized to classify cell lines 
using multiple compounds15. Even though analyzing cell lines is an efficient strategy, these results may not be 
translatable to human or even whole animal studies. Analyzing urine would provide biomarkers that change not 
only because of transformation of tumor cells, but also changes in tumor local microenvironment. This property, 
for example, may play a role in the transition of some adenocarcinomas from ductal carcinoma in situ (DCIS) to 
invasive16. This can be studied by identifying VOCs in mouse urine that are associated with tumors in the mam-
mary pad compared with the same tumors injected to the bone. The only publications that analyze mouse urine 
to discover VOC biomarkers identified metabolic trends in lung cancer17–19.
Metabolic biomarkers, including VOC biomarkers, are generally reported as panels or signatures of com-
pounds rather than individual metabolites. A panel can better identify trends and multivariate analysis can be 
cross validated for accuracy better than a single metabolite20. There are pitfalls, however, which can occur when 
building a multivariate model. For linear models, there is the potential problem of multicollinearity21, but all 
models could be unstable or overfit22,23. Utilizing overfit models is problematic because the accuracy of classi-
fication will decrease when implemented on an independent data set. Data and function perturbation are two 
techniques used to detect overfit models23.
Solid phase microextraction (SPME) coupled to gas chromatography-mass spectrometry (GC-MS) is widely 
used for VOC biomarker discovery24,25. SPME utilizes a silica-based fiber to which the VOCs in the headspace of 
the sample adsorb when the urine is heated and agitated. After incubating, the fiber is injected directly in to the 
GC-MS system where the front inlet is kept at a relatively high temperature, and the VOCs thermally desorb off 
the fiber and enter the chromatographic column where they can be separated and identified26. Analyzing mouse 
urine via SPME coupled to GC-MS as a pilot study can provide information on urinary VOCs that classify breast 
cancer from no cancer and metastasized breast cancer from localized. Also, discovering biomarkers in a simpli-
fied biological model where the conditions of the experiment can be controlled makes it easier to find endoge-
nous metabolic biomarkers. One problem which occurs when using GC-MS to analyze mouse urine is that the 
urine contains major urinary proteins (MUPs) that have hydrophobic pockets where VOCs preferentially bind. 
Therefore, the MUPs must be denatured so the VOCs can be released into the sample headspace and analyzed via 
GC-MS27. Guanidine hydrochloride (GHCl) is a well-known reagent that both denatures the MUPs significantly 
and increases the ionic strength of the sample solution which also increases the concentration of volatiles in the 
headspace of the sample28. Herein, mouse urine samples were analyzed via SPME coupled to GC-MS quadrupole 
time-of-flight (QTOF) to differentiate two different locations of mammary tumors and samples without tumor 
injection based solely on VOC composition.
Methods
Materials and Instrumentation. All BALB/c female mice utilized during the study were purchased from 
Harlan Laboratories, Indianapolis, IN, USA. 4T1.2 mammary tumor cells were attained from Dr. R. Anderson at 
the Peter MacCallum Cancer Institute in Melborne, Australia. Two cm PolyDimethylMethylSiloxane/CARboxen/
DiVinylBenzene (PDMS/CAR/DVB) SPME fibers manufactured by Supelco were purchased from Sigma Aldrich, 
and 10 mL headspace vials as well as 18 mm magnetic lids with a screw thread cap from Restek. Eight Molar 
Guanidine Hydrochloride (pH = 8.5) was purchased from Sigma Aldrich. An Agilent 7890 A GC system coupled 
to an Agilent 7200 Accurate-Mass Quadrupole Time-of-Flight MS system with a front-end PAL autosampling 
system (CTC Analytics) was utilized to incubate samples and separate/identify VOCs. The column employed 
was an Agilent HP-5ms, 5% phenylmethyl siloxane GC column of 30 meters in length, 250 micrometer internal 
diameter and 0.25 micrometer film thickness.
Mouse Urine Collection. Female BALB/c mice were kept in cages and fed the same diet to limit metabolic 
variations due to nutrition. All of the procedures conducted during this experiment were approved by Indiana 
University Animal Care and Use Committee. All experimental procedures followed the Guiding Principles in 
the Care and Use of Animals that is supported by the American Physiological Society. 4T1.2 tumor cells were 
cultured in Dulbecco’s Modified Eagle Media (DMEM). The BALB/c mice were injected in the mammary pad 
with 4T1.2 mammary tumor cells to represent localized cancer. The same cells were injected in the iliac artery of 
a different group of mice to model metastasized breast cancer. Mice not injected with any tumor cells served as 
a control. Mice injected with mammary tumors in either location will be referred to as mice with breast cancer, 
mice with mammary pad tumors as localized and mice with tumors injected in the iliac artery as metastasized 
breast cancer. Injection into the iliac artery is an accepted model of metastasized cancer29. Bone is a common 
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region where breast cancer metastasizes to because of the high affinity for bone that breast cancer cells exhibit30,31. 
The localized and metastasized tumor models were previously used and justified in literature29.
Urine was collected 18 days after the mice were injected. No visual signs of injury due to injection were 
observed when the urine was collected. Samples were collected (approximately 75 microliters) in two time peri-
ods, with the first time period collecting urine from control, mammary pad and metastasized cancer mice and 
the second urine from control and metastasized cancer mice. Mice are moved to a cage where the floor has been 
covered in fresh parafilm. Urine falls on the parafilm and is collected using pre-cleaned glass Pasteur pipettes 
into pre-cleaned glass headspace vials which were put on dry ice immediately. All the mouse urine samples were 
stored in a −80 °C freezer in a 10 mL headspace vial before analysis. All urine was collected in the morning to 
avoid and limit variation due to void times. One hour before agitation and extraction, eight M GHCl was added in 
a one to one ratio to denature the MUPs and increase the ionic strength of the sample solution.
spMe and GC-Ms QtoF. The VOCs were captured by incubating a pre-conditioned SPME fiber in urine 
headspace before analysis. SPME fibers were conditioned every day for ten minutes prior to the first run, and 
for four minutes after each run. Mouse urine samples in headspace vials were agitated and heated to 60 °C for a 
total of 30 minutes. Next, the SPME fiber was placed inside the headspace of vial through the septum for a total 
of 30 minutes while the sample continued agitating and heating at 60 °C. After extraction, the SPME fiber was 
injected into the inlet of the GC-MS QTOF at 250 °C while the mass transfer line was held at 230 °C. The oven 
temperature program implemented consisted of holding the temperature at 40 °C for the first 2 minutes of the 
chromatographic run. After, the temperature was ramped to 100 °C at a rate of 8 °C/min, followed by a 15 °C/min 
ramp to 120 °C, 8 °C/min to 180 °C, 15 °C/min to 200 °C and finally an 8 °C/min ramp to 260 °C. Data was col-
lected utilizing Agilent Chemstation software. Parameters utilized for SPME coupled to GC-MS QTOF were 
previously optimized, including: SPME fiber coating, agitation time, extraction time, agitation and extraction 
temperature, and volume of sample. Due to the limited amount of urine collected from each mouse (<100 micro-
liters), only one injection into the GC-MS system was conducted per sample.
Reproducibility of extraction procedure was tested as follows. High-density polyethylene (HDPE) virgin pel-
lets generate a consistent and complex matrix of VOCs that does not degrade substantially over time. In order to 
quantify reproducibility of the SPME extraction procedure, HDPE pellets were run on five consecutive days. The 
relative standard deviation (RSD) of the total integrated signals was 1.17%. Six representative VOCs conserved 
across samples (saturated and unsaturated hydrocarbons off-gassed by the HDPE pellets) were selected to observe 
the reproducibility of the integrated signal over five consecutive days, and the RSD values were below 6% (range 
of 1.1–5.5%) for each of the six volatiles.
Data screening and Analysis. Mass Hunter Quantitative Profinder was utilized to spectrally align mul-
tiple chromatographic peaks obtained from all samples using similarities in experimental retention time and 
mass spectrum. Profinder generates a matrix that includes all the retention times and integrated signals for every 
VOC in each sample. The log2 of the integrated signal values were calculated to transform the data matrix to an 
approximate Gaussian distribution32–34. Compounds were filtered by requiring either a two-tail Student’s T-test 
or Wilcoxon’s Rank sum test p-value < 0.1. While not all of these compounds have an alpha <0.05, they may 
still have utility at constructing a multiparametric test. In addition, p-values obtained from univariate statistical 
analysis were not corrected for multiple testing. Univariate methods were used to screen for VOCs that might 
be useful for multivariate analysis, where statistical significance can be measured through model stability testing 
including cross-validation, bootstrapping, and method perturbation. Multivariate tests can, if properly validated, 
utilize univariate compounds with broader confidence intervals20. Normality of the data was not tested, therefore, 
both a parametric and non-parametric test were employed to find statistically significant features. Individual 
VOCs that had high within class variation (collected from the two different time periods described above) were 
removed from the sample matrix as likely environmentally based differences. Hierarchical heatmaps were gen-
erated for both comparisons by z-scoring all log2 integrated signal values for all VOCs detected in every sample. 
The hierarchical heatmap was generated using a Euclidean distance metric and average linkage to generate the 
hierarchical tree (Matlab). VOCs are sorted in the hierarchical heatmap on the y-axis by similarities in concentra-
tion among the samples that were analyzed. PCA was used for visualization of patterns and outliers (no samples 
removed as outliers). Iterative LDA35, a forward selection method in which features are selected for their ability to 
discriminate between data sets22, was executed on a matrix composed of the compounds identified by univariate 
analysis. The combination of VOCS that produced the highest area under the receiver operating characteristic 
(ROC) curve generated via LDA were also tested via five-fold cross validation (Matlab) to test if the model is over-
fit (data perturbation)36. Five-fold cross validation was performed 500 times to produce an estimated ROC value. 
A 95% confidence interval for the area under the ROC associated with five-fold cross validation was obtained 
by bootstrapping the results 500 times with randomly selected samples37. Function perturbation was performed 
on the developed test matrix by implementing a logistic regression classification algorithm in Matlab to further 
test if the models are overfit23. In addition, the two test matrices of VOCs were tested for multicollinearity21 by 
performing linear regression in Matlab on the predictor and response variables. The Variable Inflation Factor 
(VIF) was measured to assess the degree of multicollinearity in the two models (cancer/no cancer and localized/
metastatic). A VIF threshold of 10 demonstrates a strong correlation between predictor values38. Iterative LDA 
was also performed on the same set of data to distinguish between all three classes of samples.
Identification of metabolites. All VOCs that were found as p < 0.1 via the Student’s T-test or Wilcoxon’s 
Rank sum test in both data sets and had low within class variation were identified utilizing Mass Hunter 
Quantitative Profinder, Mass Hunter Unknown Analysis and the NIST14 mass spectral library. NIST14 was 
uploaded to Unknown Analysis, and sample chromatograms were deconvoluted and all the features were 
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identified. The retention time and mass spectrum produced from Profinder  were used to find the corresponding 
feature in Unknown Analysis. If the retention time/mass spectrum matched, and there was a match factor higher 
than 65, the compound was identified. To confirm that identification was correct, the non-polar retention index 
(NPRI) from NIST was compared to the experimental NPRI calculated from the average retention time of the 
feature. If the NIST and experimental NPRI values were within 100 units, the compound was deemed identified. 
Pure chemical compounds were not purchased or analyzed by GC-MS QTOF to confirm the identification of 
VOC biomarkers. The Human Metabolomic Database (HMDB) was utilized to identify compounds that were 
endogenous to the human body, on the assumption that such metabolites were likely also endogenous to mice. 
VOCs that were not found on HMDB were included in the sample matrix: likely excreted compounds that were 
not in HMDB were murine-specific and endogenous, bacterial in origin, or food source related.
Results
Urine sample Collection. Urine was collected from 12 mice with no cancer, eight mice with mammary 
pad cancer and 22 mice with metastasized cancer. Of the 42 mice, analysis was only performed on urine samples 
from 36 mice because samples from six of the mice, there was less than 75 microliters present (11 no cancer, eight 
localized and 17 metastasized mouse urine samples had enough urine for processing).
Univariate Statistical Analysis and Compound Identification. To answer the question of which 
VOCs have high discriminating power to distinguish between cancer/no cancer and localized/metastasized, all 
36 samples were spectrally aligned utilizing Profinder. For cancer (n = 25)/no cancer (n = 11), this alignment 
produced 646 compounds detected in at least half of one of the two sample classes. For mammary pad (n = 8) 
and metastatic (n = 17) samples, 601 compounds were present in at least half of one of the two classes. Univariate 
statistical analysis showed that there were 226 features that could distinguish between mice with cancer and 
no cancer (p-value < 0.1 by Student’s t-test or Wilcoxon Rank sum). On the other hand, only 125 compounds 
were different between localized and metastasized breast cancer urine samples collected from the mice (p < 0.1). 
Figure 1 shows the volcano plots for the two sets. For both volcano plots, the VOCs that are highlighted and out-
lined in green have an absolute log 2-Fold Change value greater than one, and their p-value produced from the 
Student’s T-test < 0.05. Metabolites that have a positive log 2-Fold Change value are up regulated in breast cancer 
or metastatic cancer and metabolites with negative values are down regulated. In the cancer/no cancer volcano 
plot, there are 17 metabolites that meet the required statistical criteria. Out of the 17 metabolites highlighted in 
green, 14 VOCs are down regulated in breast cancer and there is a total of three VOCs which are up regulated. In 
the volcano plot for VOCs classifying localized and metastasized cancer, there are 18 metabolites that meet the 
statistical criteria; 13 of the 18 metabolites which meet the criteria are up regulated in metastasized breast cancer 
and five are down regulated. In both volcano plots, six VOCs (three that are up regulated and three that are down 
regulated) with the lowest p-values and highest absolute log 2-Fold Change values are labeled utilizing their 
abbreviations which can be seen in Tables 1 and 2. Out of the VOCs that are labeled in both plots, Benzaldehyde 
(BNZA) is the only VOC that can be observed in both volcano plots. Of the 226 features that were univariately 
different (p < 0.1) between mice with and without breast cancer, 43 VOCs (identified by mass spectrum) had low 
within class variation (means of results from time period one and time period two comparable). Similarly, of the 
125 VOCs that univariately distinguished between mice with breast cancer in the mammary pad and metasta-
sized to the bone, 30 had low within class variation.
Table 1 shows all 43 features that univariately distinguish between mouse urine samples with and without 
breast cancer (p-value < 0.1), along with their associated retention times (RT), p-values, the CAS # and if the 
VOC is up or down regulated in breast cancer. Figure 2 illustrates a hierarchical heatmap of these 43 VOCs, where 
green illustrates a low concentration, red represents a relatively high concentration and black represents mean 
values (abbreviations used in Fig. 2 correspond to the full compound names in Table 1). For each VOC, there is 
a clear difference in concentration between the two classes of samples, and most of the VOCs are down regulated 
in mouse urine samples with breast cancer, and only six up regulated. Table 2 shows the 30 features differentiating 
metastatic breast cancer from localized breast cancer, and Fig. 3 shows a hierarchical heatmap of these 30 VOCs. 
From the identified VOCs for both comparisons (breast cancer/no cancer and localized breast cancer/metastatic), 
there are 12 VOCs that can be observed in both sets of data. The 12 common VOCs found in both data sets are 
bolded and can be observed in Tables 1 and 2.
Among these VOC biomarkers for both breast cancer and metastatic breast cancer, there is a wide range 
of size, structure and functionality. There are both commonalities and very slight differences in structure and 
function in these two different sets of potential metabolic biomarkers. Of the potential biomarkers for breast 
cancer, aromatic VOCs were the most common feature and non-conjugated cyclic compounds were the second 
most common structural feature. The third most frequently observed are ketones. VOCs that contain an ether 
or ester functional group are the least observed. The potential biomarkers for metastasized breast cancer have a 
similar distribution of functional groups. The three most frequently found structural features were again ketones, 
non-conjugated cyclic VOCs and aromatics. The three least frequently observed functional groups in the local-
ized/metastasized data set are alcohols, esters and ethers. When compared to cancer/no cancer, sulfur-containing 
VOCs were less frequently occurring in the localized/metastasized data set. Also, there was one VOC that con-
tained a chlorine atom in the cancer/no cancer set and there were none in the localized/metastasized group of 
VOCs.
Multivariate statistical analysis. For both comparisons, PCA was executed utilizing all identified VOCs 
observed in Tables 1 and 2 (Fig. 4). When applied to samples with and without breast cancer, the first two princi-
pal component axes observed in Fig. 4(a) accounted for 35% of variation that exists between samples (PC 1–27%, 
PC 2–8%). When applied to the VOCs in the localized/metastasized data set, the first two principal components 
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present in Fig. 4(b) accounted for 47% of variation between samples (PC 1–36%, PC 2–11%). PCA was also 
applied to the features that have potential discriminatory power to separate all three classes, and 20 VOCs with 
relatively low p-values resulted in the first two principal component axes accounting for 42% of variation between 
all samples (PC 1–31%, PC 2–11%) (Fig. 4(c)). All three representations show good distributions and an absence 
of outliers in the data sets.
Iterative LDA was applied to find a small set of VOCs with high classification accuracy. Six VOCs (the cancer 
panel) provided a perfect separation between all mice with and without breast cancer (Fig. 5(a) plots the sam-
ples along the principle linear discriminant axes, AUC = one on ROC curve not shown). The ROC curve for the 
five-fold cross validation results discriminating between cancer and no cancer gave an estimated AUC of 0.98 
(95% confidence interval [0.85, 1.00]). The six VOCs that comprise the cancer panel are listed at the top of Table 1 
and have an asterisk to note they have been utilized for multivariate analysis. Interestingly, all features were down 
regulated in the cancer samples and showed an absolute log 2-Fold Change more than 0.5 indicating a substantial 
decrease in concentration of these VOCs in urine for mice with breast cancer. Multicollinearity of the cancer 
panel was tested and found to be insignificant (VIF = 2.5). The cancer panel was further analyzed for overfitting 
by logistic regression. This test also showed perfect separation (AUC 5-fold cross validation = 0.97 (95% confi-
dence interval [0.89, 1.00])).
Figure 1. (a) Volcano plot where statistical significance via the Student’s T-test is plotted against log 2-Fold 
Change between classes for metabolites present in at least half of one class, distinguishing between mouse 
urine with and without cancer (5-OCT = 5-Octen-1-ol, BERG = Bergamotene, BNAT = Benzeneacetaldehyde, 
BNZA = Benzaldehyde, THIO = Thiophene, 2-pentyl, FRNS = Farnesene), (b) Volcano plot in a similar 
fashion produced to distinguish between mouse urine with localized and metastasized breast cancer 
(MENA = Menadione, TRIM = 2,6,6-Trimethyl-2-cyclohexene-1,4-dione, 6-DMH = 6,6-Dimethylhepta-2,4-
diene, BNZE = Benzene, 4-ethenyl-1,2-dimethyl-, DLIM = D-Limonene).
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For the case of localized compared with metastasized breast cancer samples, iterative LDA was applied to the 
30 features that were listed in Table 2. Again, six compounds (the metastatic panel) gave a perfect separation of 
localized and metastasized mouse urine (Fig. 5(b)). Once again, five-fold cross validation was implemented and 
with cross validation, the AUC was 0.96 (95% confidence interval [0.75, 1.00]). The hierarchical heatmap in Fig. 3 
and Table 2 demonstrate that these six metabolic VOCs in the metastatic panel are evenly distributed between up 
and down regulation in metastatic breast cancer. The VOCs are listed at the top of Table 2 and have an asterisk to 
note they comprise the metastatic panel. Multicollinearity of the metastatic panel was insignificant (VIF = 3.1). 
Logistic regression was also applied on the metastatic panel of VOCs and AUC was 0.94 (95% confidence interval 








p-value Regulation CAS #
5-Octen-1-ol, (Z)-* 5-OCT 8.6 2.3E-4 1.4E-4 down 64275-73-6
Benzene, 4-ethenyl- 1,2-dimethyl-*,ǂ BNZE 10.45 4.5E-4 6.3E-4 down 27831-13-6
Bicyclo[3.1.0] hexan-2-one, 3,3,6-trimethyl-*,ǂ BCY3 8.87 0.003 7.6E-4 down 53966-40-8
Bicyclo[2.2.1]heptane, 7,7-dimethyl-2-methylene*,ǂ BCY2 8.52 0.006 0.006 down 471-84-1
Pinocarvone*,ǂ PINC 11.66 0.017 0.002 down 30460-92-5
Benzyl methyl disulfide* BMDS 15.07 0.076 0.052 down 699-10-5
Benzene, 1-ethyl-4-methoxy-ǂ BETH 11.07 3.2E-4 0.002 down 1515-95-3
Amantadine AMAN 12.61 0.001 0.008 down 768-94-5
Benzene, 1-(1,5-dimethyl-4-hexenyl)-4-methyl- BEHX 16.45 0.002 0.019 down 644-30-4
Bergamotene BERG 16.56 0.002 0.002 down 17699-05-7
1,3,5-Undecatrieneǂ UNDE 11.9 0.002 3.7E-4 down 51447-08-6
Benzeneacetaldehydeǂ BNAT 9.61 0.006 9.4E-4 down 122-78-1
Sorbic acid vinyl ester SORB 8.56 0.008 8.8E-4 down 42739-26-4
4(1 H)-Pyridone 4-PYR 8.43 0.010 0.019 up 108-96-3
(E)-α-Bisabolene CYCL 17.29 0.011 0.008 down 17627-44-0
Farnesene FRNS 16.76 0.013 0.026 up 502-61-4
Ethanone, 1-(1H-pyrrol-2-yl)- ETHP 9.93 0.015 0.013 down 1072-83-9
Himachalol HIMA 19.23 0.017 0.024 down 1891-45-8
2-Hexanone 2-HXO 4.43 0.017 0.009 down 591-78-6
Ethanone, 2-cyclohexyl-1-(1-methyl-1H-imidazol-4-yl)- ETCH 19.51 0.019 0.003 down 69393-35-7
(Z)-γ-Bisabolene 1-MCY 16.94 0.021 0.005 down 495-62-5
1-(4-butoxy-2-methylphenyl)ethanone 4-BUT 19.42 0.021 0.004 down NA
Benzenemethanol, 4-trimethyl- BEME 11.97 0.022 0.014 down 1197-01-9
Benzaldehyde, 4-ethyl- BENE 11.88 0.029 0.125 down 4748-78-1
Bisobolol BIBO 19.22 0.034 0.072 down 515-69-5
Benzene, n-butyl- BZNB 8.81 0.038 0.021 down 104-51-8
Benzene, [(methylsulfonyl)methyl]- BNMS 15.08 0.045 0.026 down 3112-90-1
Benzene, 1,3-diethyl-5-methyl- BNDI 12.75 0.050 0.050 up 2050-24-0
Formamide, N-phenyl- FORM 12.54 0.051 0.022 down 103-70-8
Benzaldehyde BNZA 7.88 0.063 0.018 up 100-52-7
2-Propanamine, 2-methyl 2-PRO 2.55 0.069 0.582 down 75-64-9
Cyclohexanol, 2,6-dimethyl- CHXO 9.99 0.069 0.302 down 5337-72-4
1,4-Pentadiene 1-PEN 1.62 0.081 0.018 down 591-93-5
D-Limonene DLIM 9.32 0.084 0.066 down 5989-27-5
Phenol, 2,4-dichloro- PHEN 11.7 0.092 0.108 down 120-83-2
2-Pentanone, 3-methyl- 2-PTM 3.78 0.097 0.070 down 565-61-7
Thiophene, 2-pentyl- THIO 11.59 0.139 0.061 up 4861-58-9
Benzene, 1-isothiocyanato-2-methyl- BISO 13.73 0.156 0.029 up 614-69-7
Hexadecane HXDC 19.31 0.158 0.056 down 544-76-3
Benzene, 1-ethenyl-4-ethyl BNET 10.39 0.173 0.029 down 3454-07-7
β-Irone 3-BUT 19.05 0.210 0.094 down 79-70-9
Terpineol TERP 12.07 0.226 0.043 down 98-55-5
(+)-α-himachalene 1-BEN 16.82 0.259 0.042 down 3853-83-6
Table 1. List of the 43 VOCs that have a p-value less than 0.1 via the Student’s T-test or Wilcoxon’s Rank sum 
test when classifying mice with no cancer and mice that have breast cancer. Features bolded are also found in 
Table 2, VOCs that have an asterisk (*) were utilized for two class LDA, and VOCs with a cross (ǂ) were utilized 
for three class LDA. All VOCs in the table were utilized to discriminate between cancer/no cancer via PCA.
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Figure 5(c) plots the samples along the first three linear discriminant axes, and it can be observed there is a per-
fect classification of mice with no cancer, localized and metastasized breast cancer. However, this model showed 
evidence of being somewhat overfit as five-fold cross validation produced an overall correct detection rate of only 
83%. The nine metabolic features are listed in Tables 1 and 2 and have a cross to note they have been utilized for 
multivariate analysis to distinguish between all three classes.
Discussion
Volcano plots, in which statistical significance via the Student’s T-test is plotted against log 2-Fold Change 
between classes for all metabolites39–41, are useful for rapidly visualizing differences between up regulated and 
down regulated metabolites: Fig. 1 shows many more VOCs down regulated in breast cancer samples and there 
are more VOCs up regulated in metastasized breast cancer model relative to localized model, but to a lesser 
degree. This indicates that there is a more even distribution of metabolites that are up and down regulated in urine 
samples collected from mice with metastasized/localized breast cancer. This can be also seen in the hierarchical 
heatmaps in Figs 2 and 3. Benzaldehyde (BNZA) is the only labeled VOC present in both volcano plots and was 
observed to be up regulated in breast cancer and down regulated in metastatic breast cancer when compared to 
localized.
Univariate statistical analysis did not yield any VOC that could discriminate perfectly between cancer and 
no cancer samples or between metastatic and localized cancer. Therefore, multivariate analysis was utilized to 
identify a set of VOCs that could classify breast cancer samples from samples collected from mice with no cancer 
and metastatic samples from localized. PCA was implemented to visualize global patterns within the data set and 
to observe if any samples are outliers. Figure 4 shows the PCA distinguishing cancer/no cancer, localized/metas-
tasized as well as localized/metastasized/no cancer, and there are no samples which are outliers. A supervised 
statistical analysis technique was implemented to increase the sensitivity and specificity for both classifications, as 







p-value Regulation CAS #
Menadione*,ǂ MENA 16.98 4.3E-4 7.1E-4 down 58-27-5
2,6-Dimethylhepta-2,4-diene*,ǂ 6-DMH 5.53 0.012 5.3E-4 up 4634-87-1
1-Octen-3-one* 1-OCT 8.26 0.040 0.136 down 4312-99-6
2,6,6-Trimethyl-2-cyclohexene-1,4-dione* TRIM 11.32 0.050 0.009 down 1125-21-9
Bicyclo [2.2.1]heptane, 7,7-dimethyl-2-methylene*,ǂ BCY2 8.52 0.069 0.072 up 471-84-1
2(3H)-Furanone, 5-hexyldihydro-* 1-FUR 16.21 0.221 0.096 up 706-14-9
Benzaldehyde BNZA 7.88 0.003 0.002 down 100-52-7
D-Limonene DLIM 9.32 0.005 0.018 up 5989-27-5
1,3,5-Undecatrieneǂ UNDE 11.9 0.007 0.007 up 51447-08-6
Benzene, 4-ethenyl- 1,2-dimethyl- BNZE 10.45 0.009 0.020 up 27831-13-6
2,6-Di-tert-butylbenzoquinone DTBQ 16.24 0.012 0.016 up 719-22-2
Hexadecane HXDC 19.31 0.018 0.003 up 544-76-3
5-methyl-2-propan-2-ylcyclohex-3-en-1-one 3-CON 13.99 0.037 0.037 down NA
4-Hexen-3-one, 4,5-dimethyl 4-HEX 8.57 0.042 0.044 up 17325-90-5
2-Propanamine, 2-methyl 2-PRO 2.55 0.050 0.044 down 75-64-9
1H-Indole, 6-methyl- 1-IND 12.73 0.052 0.052 down 3420-02-8
Ethyl (E)-4-ethoxy-2-oxobut-3-enoate ETOX 12.49 0.061 0.107 up NA
Caryophyllene CRYO 17.56 0.068 0.039 up 87-44-5
(E)-α-Bisabolene CYCL 17.29 0.070 0.097 up 17627-44-0
2-Hexenal, 2-ethyl- 2-HEX 6.82 0.072 0.086 up 645-62-5
3-Heptanone 3-HEP 6.34 0.081 0.033 up 106-35-4
1-Propanone, 2-methyl-1-(2-methylphenyl)- 1-PRO 13.85 0.083 0.082 up 2040-14-4
Farnesene FRNS 16.76 0.088 0.748 down 502-61-4
Benzeneacetaldehydeǂ BNAT 9.61 0.088 0.190 down 122-78-1
Pinocarvoneǂ PINC 11.66 0.092 0.132 down 30460-92-5
n-Tridecan-1-ol TRID 17.91 0.098 0.367 down 26248-42-0
2-Pentanone 2-PEN 2.8 0.099 0.025 up 107-87-9
Thiophene, 2-pentyl- THIO 11.59 0.197 0.058 up 4861-58-9
Quinoline, 1,2,3,4-tetrahydro- QUIN 13.19 0.326 0.051 down 635-46-1
2,4-Di-tert-butylphenol DTBP 16.8 0.030 0.018 up 128-39-2
Table 2. List of the 30 VOCs that have a p-value less than 0.1 via the Student’s T-test or Wilcoxon’s Rank sum 
test when distinguishing between mice with localized and metastasized breast cancer. Features bolded are also 
found in Table 1, VOCs that have an asterisk (*) were utilized for two class LDA, and VOCs with a cross (ǂ) were 
utilized for three class LDA. All VOCs in the table were utilized to discriminate between localized/metastasized 
via PCA.
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produces linear combinations of log2 integrated signal values from multiple VOCs to discriminate between two 
or more defined classes42,43. For each comparison, the top three features that could linearly discriminate between 
the two classes with the highest sensitivity and specificity values were generated. Next, one of the top three fea-
tures were left out, and the next best three VOCs for classification were identified to produce a combination of 
Figure 2. Hierarchical heatmap of the 43 VOCs (p-value < 0.1) different between mouse urine samples with 
and without breast cancer. Full compound names which are associated with the illustrated abbreviation can be 
observed in Table 1.
Figure 3. Hierarchical heatmap of the 30 VOCs that are (p-value < 0.1) different between mouse urine samples 
with localized breast cancer and metastasized breast cancer. Full compound names which are associated with 
the illustrated abbreviation can be observed in Table 2.
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four VOCs. A decision tree was utilized, where the best combinations were utilized to produce larger combina-
tions of VOCs to further discriminate between sample classes for both comparisons. The decision tree was con-
structed until the result was inferior or perfect separation between classes was obtained.
The six compounds that distinguish both types of breast cancer from no cancer with 100% sensitivity and 
specificity via LDA in Fig. 5(a) (the cancer panel) are all down regulated in samples with cancer, showing the 
higher metabolic utilization of cancer compared to healthy mice. While an interesting finding, this result 
could be difficult to translate to clinical research where typically one looks for biomarkers up regulated by dis-
ease. A different set of six VOCs discriminated between localized and metastasized breast cancer via LDA in 
Fig. 5(b) (the metastatic panel) with three up regulated in metastatic and three up regulated in localized breast 
cancer. These VOCs are likely related to changes of the tumor local microenvironment. Bicyclo[2.2.1]heptane, 
7,7-dimethyl-2-methylene (BCY2) was the only VOC that was found in both sets of 6 metabolites (cancer/no 
cancer and localized/metastasized). These two panels are not overfit because their average five-fold cross valida-
tion ROC values are relatively high (0.98 and 0.96 respectively) and when the Linear Discriminant function was 
perturbed with a Logistic Regression algorithm classifier, the AUC was still high (AUCs of 0.97 and 0.94, respec-
tively)22. Even though there was only one VOC used in both sets of metabolites used to discriminate between 
cancer/no cancer and localized/metastasized, it displays there is possibly a set of VOCs that can be utilized to 
classify both data sets. A set of nine VOCs from both sets of data (Tables 1 and 2) perfectly distinguished between 
all three classes via LDA in Fig. 5(c).
There is a limited number of urinary biomarkers that were found in previous studies which analyzed VOCs 
in breast cancer cell lines. The VOCs that were found both in this study in Tables 1 and 2 and in breast cancer cell 
lines include: 3-heptanone, benzaldehyde, 2,4-di-tert-butylphenol and 2-pentanone. Other than the four VOCs 
found in both mouse urine and cell lines, there are many VOCs that share common structures and functionalities. 
Figure 4. PCA utilizing (a) 43 VOCs to discriminate between mouse urine with and without breast cancer, 
(b) 30 VOCs to discriminate between mouse urine that was collected from mice that had cancer injected in the 
mammary pad (localized) and in the iliac artery (metastasized), (c) 20 VOCs to discriminate between mouse 
urine that was collected from all three classes (localized, metastasized and no cancer).
Figure 5. (a) LDA utilizing six VOCs to discriminate between mouse urine with and without breast cancer with 
100% sensitivity and specificity, (b) LDA utilizing six different VOCs to discriminate between mouse urine that 
was collected from mice that had cancer injected in the mammary pad (localized) and mice that had cancer cells 
injected in the iliac artery (metastasized) with 100% sensitivity and specificity and (c) LDA using nine VOCs 
to perfectly discriminate between mouse urine that was collected from all three classes (localized, metastasized 
and no cancer).
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One example of this was that  4-methyl-2-heptanone was discovered to be a biomarker in breast cancer cell lines, 
and  4,5-dimethyl-4-hexen-3-one was found to be a biomarker for breast cancer and metastatic breast cancer in 
mouse urine3,15. Interestingly, the mouse urine contained more unsaturated compounds than the breast cancer 
cell lines. Even though there were not many VOCs that were detected as potential biomarkers for breast cancer in 
mouse urine that were also observed in breast cancer cell lines, it still gives confirmation that some of the VOCs 
present in urine that change significantly are due to changes in the tumor itself. Since many metabolic VOC bio-
markers for metastatic breast cancer were not observed in cell lines, many biomarkers detected in mouse urine 
may be changing concentration due to interactions of the tumor cells and the local microenvironment. There were 
also a small set of potential urinary biomarkers for breast cancer found in this study that were found in biological 
breath in humans with breast cancer10,11. 1,4-pentadiene, D-limonene and 2,6 di-tert-butylbenzoquinone were 
found in both human breath and mouse urine as potential biomarkers for breast cancer. Again, even though 
there were a limited number of common VOCs, there were many similarities in structure between the sets of 
VOCs. Many aromatic VOCs and ketones were found in biological breath and mouse urine to be potential volatile 
markers of breast cancer10–13. Finally, it is noted that one study has reported VOCs from human urine, comparing 
women with invasive breast cancer with controls (largely men) with no cancer14. Their analysis utilized acidified 
samples which highlight different VOC types than pH neutral or basic samples15, and they analyzed only invasive 
cancer, so their results and ours would not be expected to be the same.
Many of the potential biomarkers for breast cancer are involved in the biosynthesis of terpenoids; these VOCs 
include bicyclo[2.2.1]heptane, 7,7-dimethyl-2-methylene, farnesene, caryophyllene, D-limonene, pinocarvone, 
himachalol, himachalene, bisabolol, bisabolene and other VOCs in Table 1. Terpenes and terpenoids have an anti-
oxidant and therapeutic effect on cancerous tumor cells44, which is fascinating because they were largely depleted 
in the samples with cancer. This study employed a simplified model for comparing localized and metastatic breast 
cancer in which the same tumor cells are injected into different sites (mammary pad versus iliac artery). The 
first result was that a panel of 6 VOCs can be used to classify whether mice had either form of cancer: the test 
gave a perfect separation using either of two classification models, LDA or logistic regression, with high values 
for cross validation/CI testing. Further, the study identified a separate metastatic panel that was able to classify 
tumor location perfectly via LDA or logistic regression. This study shows that not only do VOCs change due to an 
alteration in metabolism (cancer/no cancer model), but it also shows unique VOCs released by specific tumor – 
microenvironment interactions (localized/metastasized model). This study demonstrates the potential of volatile 
metabolomics to identify biological markers tied to breast cancer. One limitation is the study was carried out in a 
controlled environment on immune-compromised mice. While greater metabolic heterogeneity will be present 
in human samples, the same or similar biomarkers likely can be used to better explore and understand tumor/
microenvironment interactions in humans. Similar metabolic biomarkers found in human urine can inspire the 
development of an inexpensive, accurate and noninvasive biological assay for breast cancer.
Data Availability
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References
 1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International 
journal of cancer 136, E359–E386, https://doi.org/10.1002/ijc.29210 (2015).
 2. Kennecke, H. et al. Metastatic behavior of breast cancer subtypes. Journal of clinical oncology 28, 3271–3277, https://doi.org/10.1200/
JCO.2009.25.9820 (2010).
 3. Lavra, L. et al. Investigation of VOCs associated with different characteristics of breast cancer cells. Scientific Reports 5, 13246, 
https://doi.org/10.1038/srep13246 (2015).
 4. Krassenstein, R. et al. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clinical cancer research 10, 
28–32, https://doi.org/10.1158/1078-0432 (2004).
 5. Suzuki, M., Nishiumi, S., Matsubara, A., Azuma, T. & Yoshida, M. Metabolome analysis for discovering biomarkers of 
gastroenterological cancer. Journal of Chromatography B 966, 59–69, https://doi.org/10.1016/j.jchromb.2014.02.042 (2014).
 6. Wu, W. & Zhao, S. Metabolic changes in cancer: beyond the Warburg effect. Acta biochimica et biophysica Sinica 45, 18–26, https://
doi.org/10.1093/abbs/gms104 (2013).
 7. Albu, J. B. et al. Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. Diabetes 59, 
627–633, https://doi.org/10.2337/db09-1239 (2010).
 8. Ceccarini, A. et al. Breath analysis: analytical methodologies and clinical applications. Analytical techniques for clinical chemistry: 
methods and applications, 651–689, https://doi.org/10.1002/9781118271858.ch23 (2012).
 9. Ali, I. et al. Role of chromatography for monitoring of breast cancer biomarkers. Recent Patents on Biomarkers 1, 89–97 (2011).
 10. Phillips, M. et al. Volatile biomarkers in the breath of women with breast cancer. Journal of breath research 4, 026003, https://doi.
org/10.1088/1752-7155/4/2/026003 (2010).
 11. Phillips, M. et al. Volatile markers of breast cancer in the breath. The breast journal 9, 184–191, https://doi.org/10.1046/j.1524-
4741.2003.09309.x (2003).
 12. Peng, G. et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. 
British Journal of Cancer 103, 542–551, https://doi.org/10.1038/sj.bjc.6605810 (2010).
 13. Speiser, D. et al. Volatile organic compounds (VOCs) in exhaled breath of patients with breast cancer in a clinical setting. Ginekologia 
polska 83 (2012).
 14. Silva, C. L., Passos, M. & Câmara, J. S. Solid phase microextraction, mass spectrometry and metabolomic approaches for detection 
of potential urinary cancer biomarkers—a powerful strategy for breast cancer diagnosis. Talanta 89, 360–368, https://doi.
org/10.1016/j.talanta.2011.12.041 (2012).
 15. Silva, C. L., Perestrelo, R., Silva, P., Tomás, H. & Câmara, J. S. Volatile metabolomic signature of human breast cancer cell lines. Sci 
Rep 7, 43969, https://doi.org/10.1038/srep43969 (2017).
 16. Giussani, M., Merlino, G., Cappelletti, V., Tagliabue, E. & Daidone, M. G. In Seminars in cancer biology. 3–10, https://doi.
org/10.1016/j.semcancer.2015.09.012 (Elsevier).
 17. Hanai, Y. et al. Analysis of volatile organic compounds released from human lung cancer cells and from the urine of tumor-bearing 
mice. Cancer cell international 12, 7, https://doi.org/10.1186/1475-2867-12-7 (2012).
1 1Scientific RepoRts |          (2019) 9:2526  | https://doi.org/10.1038/s41598-019-38920-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
 18. Matsumura, K. et al. Urinary volatile compounds as biomarkers for lung cancer: a proof of principle study using odor signatures in 
mouse models of lung cancer. PLoS One 5, e8819, https://doi.org/10.1371/journal.pone.0008819 (2010).
 19. Hanai, Y. et al. Urinary volatile compounds as biomarkers for lung cancer. Bioscience, biotechnology, and biochemistry 76, 679–684, 
https://doi.org/10.1271/bbb.110760 (2012).
 20. Saccenti, E., Hoefsloot, H. C., Smilde, A. K., Westerhuis, J. A. & Hendriks, M. M. Reflections on univariate and multivariate analysis 
of metabolomics data. Metabolomics 10, 361–374, https://doi.org/10.1007/s11306-013-0598-6 (2014).
 21. Belsley, D. A. A guide to using the collinearity diagnostics. Computer Science in Economics and Management 4, 33–50, https://doi.
org/10.1007/BF00426854 (1991).
 22. Xia, J., Broadhurst, D. I., Wilson, M. & Wishart, D. S. Translational biomarker discovery in clinical metabolomics: an introductory 
tutorial. Metabolomics: Official journal of the Metabolomic Society 9, 280–299, https://doi.org/10.1007/s11306-012-0482-9 (2013).
 23. He, Z. & Yu, W. Stable feature selection for biomarker discovery. Computational biology and chemistry 34, 215–225 (2010).
 24. Rudnicka, J., Kowalkowski, T., Ligor, T. & Buszewski, B. Determination of volatile organic compounds as biomarkers of lung cancer 
by SPME–GC–TOF/MS and chemometrics. Journal of Chromatography B 879, 3360–3366, https://doi.org/10.1016/j.
jchromb.2011.09.001 (2011).
 25. Schmidt, K. & Podmore, I. Solid phase microextraction (SPME) method development in analysis of volatile organic compounds 
(VOCs) as potential biomarkers of cancer. Journal of Molecular Biomarkers & Diagnosis 2015, https://doi.org/10.4172/21559929.1000253 
(2015).
 26. Zhang, Z., Yang, M. J. & Pawliszyn, J. Solid-phase microextraction. A solvent-free alternative for sample preparation. Analytical 
chemistry 66, 844A–853A, https://doi.org/10.1021/ac00089a001 (1994).
 27. Kwak, J. et al. Differential binding between volatile ligands and major urinary proteins due to genetic variation in mice. Physiology 
& behavior 107, 112–120, https://doi.org/10.1016/j.physbeh.2012.06.008 (2012).
 28. Davison, P. F. Proteins in denaturing solvents: gel exclusion studies. Science 161, 906–907, https://doi.org/10.1126/
science.161.3844.906 (1968).
 29. Minami, K. et al. Inhibitory Effects of Dopamine Receptor D1 Agonist on Mammary Tumor and Bone Metastasis. Scientific Reports 
7, 45686, https://doi.org/10.1038/srep45686 (2017).
 30. Mundy, G. R. Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer 2, 584, 
https://doi.org/10.1038/nrc867 (2002).
 31. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer cell 3, 537–549, https://doi.org/10.1016/
S1535-6108(03)00132-6 (2003).
 32. Feng, C., Wang, H., Lu, N. & Tu, X. M. Log transformation: application and interpretation in biomedical research. Statistics in 
medicine 32, 230–239, https://doi.org/10.1002/sim.5486 (2013).
 33. Changyong, F. et al. Log-transformation and its implications for data analysis. Shanghai archives of psychiatry 26, 105, https://doi.
org/10.3969/j.issn.1002-0829.2014.02.009 (2014).
 34. Olivier, J., Johnson, W. D. & Marshall, G. D. The logarithmic transformation and the geometric mean in reporting experimental IgE 
results: what are they and when and why to use them? Annals of Allergy, Asthma & Immunology 100, 333–337, https://doi.
org/10.1016/S1081-1206(10)60595-9 (2008).
 35. Siegel, A. et al. Analyzing breath samples of hypoglycemic events in type 1 diabetes patients: towards developing an alternative to 
diabetes alert dogs. Journal of Breath Research 11, https://doi.org/10.1088/1752-7163/aa6ac6 (2017).
 36. Babyak, M. A. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. 
Psychosomatic medicine 66, 411–421 (2004).
 37. van der Schaaf, A. et al. Multivariate modeling of complications with data driven variable selection: guarding against overfitting and 
effects of data set size. Radiotherapy and Oncology 105, 115–121, https://doi.org/10.1016/j.radonc.2011.12.006 (2012).
 38. Joseph, F., Hair, J., Black, W., Babin, B. & Anderson, R. Multivariate Data Analysis, 7th Edition (2010).
 39. Patti, G. J. et al. A view from above: cloud plots to visualize global metabolomic data. Analytical chemistry 85, 798–804, https://doi.
org/10.1021/ac3029745 (2012).
 40. Hur, M. et al. A global approach to analysis and interpretation of metabolic data for plant natural product discovery. Natural product 
reports 30, 565–583, https://doi.org/10.1039/c3np20111b (2013).
 41. Feng, Q. et al. Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated 
with coronary heart disease. Scientific reports 6, 22525, https://doi.org/10.1038/srep22525 (2016).
 42. Izenman, A. J. Modern multivariate statistical techniques. Regression, classification and manifold learning, https://doi.
org/10.1007/978-0-387-78189-1_8 (2008).
 43. Mika, S., Ratsch, G., Weston, J., Scholkopf, B. & Mullers, K.-R. In Neural networks for signal processing IX, IEEE signal processing 
society workshop, 41–48, https://doi.org/10.1007/978-0-387-78189-1_8 (1999).
 44. Rabi, T. & Bishayee, A. Terpenoids and breast cancer chemoprevention. Breast cancer research and treatment 115, 223–239, https://
doi.org/10.1007/s10549-008-0118-y (2009).
Acknowledgements
The authors would like to thank Ali Daneshkhah for all the time he has put in to improve statistical analysis 
techniques and writing the Matlab code for statistical analysis, Solveig Naumann for preliminary analysis and 
optimization of procedure. The authors would finally like to thank the National Science Foundation for funding 
researchers to provide statistical analysis support involved in this project and Agilent Technologies for grant 
money that provided the lab group with the proper instrumentation to conduct analysis.
Author Contributions
M.A. and H.Y. designed the experiments used in this study. S.L. injected the breast cancer cells in the mice 
and collected their urine, M.W. and M.T. aliquoted and prepared the mouse urine samples. M.W., M.T. and 
P.A. analyzed the samples via GC-MS QTOF. M.W., A.S. and M.A. performed data screening, all the statistical 
analysis, and wrote the manuscript. All authors reviewed the manuscript.
Additional Information
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
1 2Scientific RepoRts |          (2019) 9:2526  | https://doi.org/10.1038/s41598-019-38920-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
